▲ +15.33% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Accolade in the last 3 months. The average price target is $55.00, with a high forecast of $62.00 and a low forecast of $39.00. The average price target represents a 15.33% upside from the last price of $47.69.
The current consensus among 12 investment analysts is to buy stock in Accolade.
Accolade, Inc. develops and provides technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and with multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. Its customers are primarily employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.